Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index; 1 of the 9 sources its claims cite were checked for support.
Abstract
BACKGROUND: The severe acute respiratory syndrome (SARS) has recently been identified as a new clinical entity. SARS is thought to be caused by an unknown infectious agent. METHODS: Clinical specimens from patients with SARS were searched for unknown viruses with the use of cell cultures and molecular techniques. RESULTS: A novel coronavirus was identified in patients with SARS. The virus was isolated in cell culture, and a sequence 300 nucleotides in length was obtained by a polymerase-chain-reaction (PCR)-based random-amplification procedure. Genetic characterization indicated that the virus is only distantly related to known coronaviruses (identical in 50 to 60 percent of the nucleotide sequence). On the basis of the obtained sequence, conventional and real-time PCR assays for specific and sensitive detection of the novel virus were established. Virus was detected in a variety of clinical specimens from patients with SARS but not in controls. High concentrations of viral RNA of up to 100 million molecules per milliliter were found in sputum. Viral RNA was also detected at extremely low concentrations in plasma during the acute phase and in feces during the late convalescent phase. Infected patients showed seroconversion on the Vero cells in which the virus was isolated. CONCLUSIONS: The novel coronavirus might have a role in causing SARS.
Overview
CoChat Summary
## TL;DR
The paper identifies a previously unknown coronavirus in patients with severe acute respiratory syndrome (SARS) and provides PCR and serologic evidence linking it to the illness. It also reports that viral RNA was found at very high levels in sputum, with lower-level detection in plasma and later in stool, supporting a respiratory infection with possible additional shedding routes.
## Key findings
- A novel coronavirus was isolated from sputum of the index patient after 6 days of incubation in Vero-cell culture, and a 300-nucleotide sequence was obtained by random RT-PCR.
- Genetic analysis found the virus was only distantly related to known coronaviruses, with the BNI-1 sequence differing by 39% to 46% from known sequences and by 50% to 60% identical nucleotide sequence to known coronaviruses.
- In the Hanoi outbreak panel, the virus was detected in 100% of patients with probable SARS, 23% of those with suspected SARS, and 0% of healthy contacts.
- Quantitative PCR found viral RNA concentrations of up to 100 million molecules per milliliter in sputum; the index patient also had RNA in plasma at 190 (day 9) and stool on day 25, and Contact 1 had 6.3 × 10^4 in sputum and 4.1 × 10^5 in BAL.
## Methods
- Clinical specimens from SARS patients were screened for known and unknown pathogens using cell culture, electron microscopy, PCR, antigen ELISA, serology, and sequence/phylogenetic analysis.
- The study examined specimens from 3 patients in Frankfurt (index patient, Contact 1, Contact 2) and a panel of 49 specimens from 18 suspected/probable SARS patients and 21 healthy contacts in Hanoi, plus 54 stool controls from Germany.
- A random RT-PCR approach and subsequent nested and real-time RT-PCR assays were developed to identify and quantify the novel virus, with specificity tested against several other coronaviruses.
## Limitations
- The paper itself states that larger studies with appropriate control groups are needed to verify or reject the hypothesis that this virus causes SARS.
- The authors note that the antibody response might not be definitively directed against the novel coronavirus, because the antigen used in serology came from primary cultures; they say this should be tested with plaque-purified virus or recombinant proteins.
- Evidence of causation is not established here; the paper shows association and detection in patients, but the conclusion is only that the virus “might have a role” in causing SARS.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
1 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The presence of viral RNA in stool of the patients late during convalescence is reminiscent of characteristics of other coronaviruses. 13”
What the sources say
- Partly supportedcites [13] matched to “Evaluation of concurrent shedding of bovine coronavirus via the respiratory tract and enteric route in feedlot cattle” (2001) sourceExperimental — accuracy not yet measured
Our copy of Cho et al (2001) supports only the general point that a bovine coronavirus is present/shed in feces: fecal samples from 56 feedlot steers were positive for BCV by antigen-capture ELISA and virus isolation (Results, p. 1; Materials and Methods, Sample Collections), and the Discussion (p. 6) notes 22% of fecal samples from cattle without diarrhea were antigen-positive, suggesting they 'had diarrhea during shipping or at the auction barn and were still shedding BCV'. The specific elements the citing sentence attributes are absent: detection was of antigen/infectious virus, not viral RNA (no RT-PCR assay appears anywhere in our copy; RT-PCR of feces belongs to a work it cites, Tsunemitsu and Saif, ref 35), samples were taken only on days 0, 4, 14 and 21 after arrival rather than late during convalescence, in cattle rather than human patients, and the paper makes no comparative statement about shared characteristics of other coronaviruses. (LLM, conf=0.62)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infected patients showed seroconversion on the Vero cells in which the virus was isolated.”
- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“About 20 distinct DNA fragments were obtained and sequenced.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Three of the fragments did not match any nucleotide sequence in the data base.”
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“since there was serologic evidence of an acute infection with this virus in our index patient and also in Contact 1”
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
50 more claims
Create a free account to see all 75 claims and to verify the 7 references still open.
- It may state two separate claims as one. 11
- Probably not a substantial claim. 11
Citations
Cites
PHYLIP-Phylogeny inference package (Version 3.2)
Felsenstein, J. (1989) · Cladistics · Cited by 17,682
Identification of Severe Acute Respiratory Syndrome in Canada
Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030634 · Cited by 1,132
A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong
Tsang, K. W., Ho, P. L., Ooi, G. C., Yee, W. K., Wang, T., Chan-Yeung, M., Lam, W. K., Seto, W. H., Yam, L. Y., Cheung, T. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030666 · Cited by 1,017
Viruses and bacteria in the etiology of the common cold
Mäkelä, M. J., Puhakka, T., Ruuskanen, O., Leinonen, M., Saikku, P., Kimpimäki, M., Blomqvist, S., Hyypiä, T., & Arstila, P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.539-542.1998 · Cited by 768
Drosten, C., Göttig, S., Schilling, S., Asper, M., Panning, M., Schmitz, H., & Günther, S. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.7.2323-2330.2002 · Cited by 631
Self-citationImported Lassa Fever in Germany: Molecular Characterization of a New Lassa Virus Strain
Günther, S., Emmerich, P., Laue, T., Kühle, O., Asper, M., Jung, A., Grewing, T., ter Meulen, J., & Schmitz, H. (2000) · Emerging Infectious Diseases · doi:10.3201/eid0605.000504 · Cited by 200
Self-citationStephensen, C. B., Casebolt, D. B., & Gangopadhyay, N. N. (1999) · Virus Research · doi:10.1016/s0168-1702(99)00017-9 · Cited by 135
Cho, K.-O., Hoet, A. E., Loerch, S. C., Wittum, T. E., & Saif, L. J. (2001) · American Journal of Veterinary Research · doi:10.2460/ajvr.2001.62.1436 · Cited by 88
TTV a common virus, but pathogenic?
Cossart, Y. E. (1998) · The Lancet · doi:10.1016/s0140-6736(05)77802-8 · Cited by 44
HGV: hepatitis G virus or harmless G virus?
Kew, M. C., & Kassianides, C. (1996) · The Lancet · doi:10.1016/s0140-6736(96)98020-4 · Cited by 39
Research works printed but not linked: 2
- 2003, Wkly Epidemiol Rec, 78, 81
- 2003, Wkly Epidemiol Rec, 78, 73
Cited by
Items 101–200 of 1,020
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Lei, J., Kusov, Y., & Hilgenfeld, R. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.001 · Cited by 727
Network theory and SARS: predicting outbreak diversity
Meyers, L. A., Pourbohloul, B., Newman, M. E. J., Skowronski, D. M., & Brunham, R. C. (2005) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.07.026 · Cited by 705
“More than two years since the first case of severe acute respiratory syndrome (SARS), a respiratory illness caused by a novel coronavirus, occurred in Guangdong province of China (November, 2002) and more than 18 months since the syndrome was first recognized outside of Asia (in Canada on March 13, 2003) , its pattern…”
BackgroundThe 2019‐new coronavirus epidemic: Evidence for virus evolution
Benvenuto, D., Giovanetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., & Ciccozzi, M. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25688 · Cited by 713
Wang, H., Yang, P., Liu, K., Guo, F., Zhang, Y., Zhang, G., & Jiang, C. (2008) · Cell Research · doi:10.1038/cr.2008.15 · Cited by 707
Traggiai, E., Becker, S., Subbarao, K., Kolesnikova, L., Uematsu, Y., Gismondo, M. R., Murphy, B. R., Rappuoli, R., & Lanzavecchia, A. (2004) · Nature Medicine · doi:10.1038/nm1080 · Cited by 697
“The outbreak of SARS in March 2003 caused by SARS-CoV represents the most recent threat to human health [14] [15] [16] [17] .”
BackgroundSelf-citationEnteric involvement of severe acute respiratory syndrome-associated coronavirus infection
Leung, W. K., To, K.-F., Chan, P. K. S., Chan, H. L. Y., Wu, A. K. L., Lee, N., Yuen, K. Y., & Sung, J. J. Y. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01215-0 · Cited by 639
Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV
Darnell, M. E. R., Subbarao, K., Feinstone, S. M., & Taylor, D. R. (2004) · Journal of Virological Methods · doi:10.1016/j.jviromet.2004.06.006 · Cited by 695
Inhibition of SARS-CoV 3CL protease by flavonoids
Jo, S., Kim, S., Shin, D. H., & Kim, M.-S. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1690480 · Cited by 685
Wong, S. K., Li, W., Moore, M. J., Choe, H., & Farzan, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c300520200 · Cited by 694
Clinical characteristics of 82 cases of death from COVID-19
Zhang, B., Zhou, X., Qiu, Y., Song, Y., Feng, F., Feng, J., Song, Q., Jia, Q., & Wang, J. (2020) · PLOS ONE · doi:10.1371/journal.pone.0235458 · Cited by 683
Helmy, Y. A., Fawzy, M., Elaswad, A., Sobieh, A., Kenney, S. P., & Shehata, A. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041225 · Cited by 692
Shulla, A., Heald-Sargent, T., Subramanya, G., Zhao, J., Perlman, S., & Gallagher, T. (2011) · Journal of Virology · doi:10.1128/jvi.02062-10 · Cited by 693
Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human
Song, H.-D., Tu, C.-C., Zhang, G.-W., Wang, S.-Y., Zheng, K., Lei, L.-C., Chen, Q.-X., Gao, Y.-W., Zhou, H.-Q., Xiang, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409608102 · Cited by 701
Self-citationCOVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives
Sun, J., He, W.-T., Wang, L., Lai, A., Ji, X., Zhai, X., Li, G., Suchard, M. A., Tian, J., Zhou, J., et al. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.008 · Cited by 685
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E. F., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 655
Fan, Y., Zhao, K., Shi, Z.-L., & Zhou, P. (2019) · Viruses · doi:10.3390/v11030210 · Cited by 674
Adenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
COVID-19: Immunology and treatment options
Felsenstein, S., Herbert, J. A., McNamara, P. S., & Hedrich, C. M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108448 · Cited by 669
From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · The FEBS Journal · doi:10.1111/febs.12936 · Cited by 660
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W.-P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K., & Nabel, G. J. (2004) · Nature · doi:10.1038/nature02463 · Cited by 665
Coronavirus Disease 2019: Coronaviruses and Blood Safety
Chang, L., Yan, Y., & Wang, L. (2020) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2020.02.003 · Cited by 659
In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine
Keyaerts, E., Vijgen, L., Maes, P., Neyts, J., & Ranst, M. V. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.08.085 · Cited by 649
CHAN‐YEUNG, M., & XU, R. (2003) · Respirology · doi:10.1046/j.1440-1843.2003.00518.x · Cited by 577
COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far
Khan, M., Adil, S. F., Alkhathlan, H. Z., Tahir, M. N., Saif, S., Khan, M., & Khan, S. T. (2020) · Molecules · doi:10.3390/molecules26010039 · Cited by 584
Point-of-care diagnostics for infectious diseases: From methods to devices
Wang, C., Liu, M., Wang, Z., Li, S., Deng, Y., & He, N. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101092 · Cited by 622
History and Recent Advances in Coronavirus Discovery
Kahn, J. S., & McIntosh, K. (2005) · Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000188166.17324.60 · Cited by 619
Iwata-Yoshikawa, N., Okamura, T., Shimizu, Y., Hasegawa, H., Takeda, M., & Nagata, N. (2019) · Journal of Virology · doi:10.1128/jvi.01815-18 · Cited by 618
Ashour, H. M., Elkhatib, W. F., Rahman, M. M., & Elshabrawy, H. A. (2020) · Pathogens · doi:10.3390/pathogens9030186 · Cited by 607
Identification of natural compounds with antiviral activities against SARS-associated coronavirus
LI, S., CHEN, C., ZHANG, H., GUO, H., WANG, H., WANG, L., ZHANG, X., HUA, S., YU, J., & XIAO, P. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.02.007 · Cited by 602
ter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S. W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 612
Self-citationShi, Y., Wang, G., Cai, X.-P., Deng, J.-W., Zheng, L., Zhu, H.-H., Zheng, M., Yang, B., & Chen, Z. (2020) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.b2000083 · Cited by 580
A previously undescribed coronavirus associated with respiratory disease in humans
Fouchier, R. A. M., Hartwig, N. G., Bestebroer, T. M., Niemeyer, B., de Jong, J. C., Simon, J. H., & Osterhaus, A. D. M. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400762101 · Cited by 598
Self-citationPathology and Pathogenesis of Severe Acute Respiratory Syndrome
Gu, J., & Korteweg, C. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.061088 · Cited by 592
Wen, C.-C., Kuo, Y.-H., Jan, J.-T., Liang, P.-H., Wang, S.-Y., Liu, H.-G., Lee, C.-K., Chang, S.-T., Kuo, C.-J., Lee, S.-S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070295s · Cited by 576
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Gui, M., Song, W., Zhou, H., Xu, J., Chen, S., Xiang, Y., & Wang, X. (2017) · Cell Research · doi:10.1038/cr.2016.152 · Cited by 589
Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
Corman, V. M., Eckerle, I., Bleicker, T., Zaki, A., Landt, O., Eschbach-Bludau, M., van Boheemen, S., Gopal, R., Ballhause, M., Bestebroer, T. M., et al. (2012) · Eurosurveillance · doi:10.2807/ese.17.39.20285-en · Cited by 561
Self-citationNieto-Torres, J. L., DeDiego, M. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Fernandez-Delgado, R., Castaño-Rodriguez, C., Alcaraz, A., Torres, J., Aguilella, V. M., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004077 · Cited by 559
SARS — beginning to understand a new virus
Stadler, K., Masignani, V., Eickmann, M., Becker, S., Abrignani, S., Klenk, H.-D., & Rappuoli, R. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro775 · Cited by 557
Self-citationStability and inactivation of SARS coronavirus
Rabenau, H. F., Cinatl, J., Morgenstern, B., Bauer, G., Preiser, W., & Doerr, H. W. (2005) · Medical Microbiology and Immunology · doi:10.1007/s00430-004-0219-0 · Cited by 558
Self-citationTseng, C.-T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P. C., Garron, T., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 561
Lin, C.-W., Tsai, F.-J., Tsai, C.-H., Lai, C.-C., Wan, L., Ho, T.-Y., Hsieh, C.-C., & Chao, P.-D. L. (2005) · Antiviral Research · doi:10.1016/j.antiviral.2005.07.002 · Cited by 545
Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition
Ryu, Y. B., Jeong, H. J., Kim, J. H., Kim, Y. M., Park, J.-Y., Kim, D., Naguyen, T. T. H., Park, S.-J., Chang, J. S., Park, K. H., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.035 · Cited by 546
Severe Acute Respiratory Syndrome Coronavirus Viroporin 3a Activates the NLRP3 Inflammasome
Chen, I.-Y., Moriyama, M., Chang, M.-F., & Ichinohe, T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.00050 · Cited by 547
SARS-COV-2 infection in children and newborns: a systematic review
Liguoro, I., Pilotto, C., Bonanni, M., Ferrari, M. E., Pusiol, A., Nocerino, A., Vidal, E., & Cogo, P. (2020) · European Journal of Pediatrics · doi:10.1007/s00431-020-03684-7 · Cited by 552
Host Factors in Coronavirus Replication
de Wilde, A. H., Snijder, E. J., Kikkert, M., & van Hemert, M. J. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_25 · Cited by 546
Sui, J., Li, W., Murakami, A., Tamin, A., Matthews, L. J., Wong, S. K., Moore, M. J., Tallarico, A. S. C., Olurinde, M., Choe, H., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307140101 · Cited by 550
Hui, D. S. (2005) · Thorax · doi:10.1136/thx.2004.030205 · Cited by 531
Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis
Bustin, S. A., & Mueller, R. (2005) · Clinical Science · doi:10.1042/cs20050086 · Cited by 529
Ogando, N. S., Dalebout, T. J., Zevenhoven-Dobbe, J. C., Limpens, R. W. A. L., van der Meer, Y., Caly, L., Druce, J., de Vries, J. J. C., Kikkert, M., Bárcena, M., et al. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001453 · Cited by 551
Angelini, M. M., Akhlaghpour, M., Neuman, B. W., & Buchmeier, M. J. (2013) · mBio · doi:10.1128/mbio.00524-13 · Cited by 527
Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction
HO, T., WU, S., CHEN, J., LI, C., & HSIANG, C. (2007) · Antiviral Research · doi:10.1016/j.antiviral.2006.04.014 · Cited by 516
Montopoli, M., Zumerle, S., Vettor, R., Rugge, M., Zorzi, M., Catapano, C. V., Carbone, G. M., Cavalli, A., Pagano, F., Ragazzi, E., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.479 · Cited by 518
Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms
Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., et al. (2020) · Science · doi:10.1126/science.abe3354 · Cited by 510
Epidemiology, transmission dynamics and control of SARS: the 2002–2003 epidemic
Anderson, R. M., Fraser, C., Ghani, A. C., Donnelly, C. A., Riley, S., Ferguson, N. M., Leung, G. M., Lam, T. H., & Hedley, A. J. (2004) · Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences · doi:10.1098/rstb.2004.1490 · Cited by 509
Frieman, M., Yount, B., Heise, M., Kopecky-Bromberg, S. A., Palese, P., & Baric, R. S. (2007) · Journal of Virology · doi:10.1128/jvi.01012-07 · Cited by 507
Severe Acute Respiratory Syndrome
Hui, D. S. C., & Zumla, A. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.07.001 · Cited by 506
Nieto-Torres, J. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Castaño-Rodriguez, C., Fernandez-Delgado, R., Torres, J., Aguilella, V. M., & Enjuanes, L. (2015) · Virology · doi:10.1016/j.virol.2015.08.010 · Cited by 511
Snijder, E. J., van der Meer, Y., Zevenhoven-Dobbe, J., Onderwater, J. J. M., van der Meulen, J., Koerten, H. K., & Mommaas, A. M. (2006) · Journal of Virology · doi:10.1128/jvi.02501-05 · Cited by 512
Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C. R., Xiong, H., Farmar, J., Debnath, A. K., Tien, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15788-7 · Cited by 505
Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent
Mazzoni, A., Salvati, L., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Mencarini, J., Caporale, R., Peruzzi, B., Antonelli, A., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138554 · Cited by 502
NGAI, J. C., KO, F. W., NG, S. S., TO, K., TONG, M., & HUI, D. S. (2010) · Respirology · doi:10.1111/j.1440-1843.2010.01720.x · Cited by 510
SARS-CoV-2 infects cells after viral entry via clathrin-mediated endocytosis
Bayati, A., Kumar, R., Francis, V., & McPherson, P. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100306 · Cited by 499
Malik, Y. S., Sircar, S., Bhat, S., Sharun, K., Dhama, K., Dadar, M., Tiwari, R., & Chaicumpa, W. (2020) · Veterinary Quarterly · doi:10.1080/01652176.2020.1727993 · Cited by 498
Xu, J., Zhong, S., Liu, J., Li, L., Li, Y., Wu, X., Li, Z., Deng, P., Zhang, J., Zhong, N., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/444461 · Cited by 494
Yang, Z.-Y., Huang, Y., Ganesh, L., Leung, K., Kong, W.-P., Schwartz, O., Subbarao, K., & Nabel, G. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5642-5650.2004 · Cited by 490
Zhao, D., Yao, F., Wang, L., Zheng, L., Gao, Y., Ye, J., Guo, F., Zhao, H., & Gao, R. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa247 · Cited by 488
Small Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells
Yi, L., Li, Z., Yuan, K., Qu, X., Chen, J., Wang, G., Zhang, H., Luo, H., Zhu, L., Jiang, P., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.20.11334-11339.2004 · Cited by 485
Totura, A. L., Whitmore, A., Agnihothram, S., Schäfer, A., Katze, M. G., Heise, M. T., & Baric, R. S. (2015) · mBio · doi:10.1128/mbio.00638-15 · Cited by 455
Yu, L., Wu, S., Hao, X., Dong, X., Mao, L., Pelechano, V., Chen, W.-H., & Yin, X. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa102 · Cited by 477
Tracking virus outbreaks in the twenty-first century
Grubaugh, N. D., Ladner, J. T., Lemey, P., Pybus, O. G., Rambaut, A., Holmes, E. C., & Andersen, K. G. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0296-2 · Cited by 485
Xue, X., Yu, H., Yang, H., Xue, F., Wu, Z., Shen, W., Li, J., Zhou, Z., Ding, Y., Zhao, Q., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02114-07 · Cited by 473
Treatment of SARS with human interferons
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., & Doerr, H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13973-6 · Cited by 467
Self-citationShi, C.-S., Qi, H.-Y., Boularan, C., Huang, N.-N., Abu-Asab, M., Shelhamer, J. H., & Kehrl, J. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303196 · Cited by 473
Guidelines for the management of adult lower respiratory tract infections - Summary
Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., Ortqvist, A., Schaberg, T., Torres, A., van der Heijden, G., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03602.x · Cited by 468
Chemokine up-regulation in SARS-coronavirus–infected, monocyte-derived human dendritic cells
Law, H. K. W., Cheung, C. Y., Ng, H. Y., Sia, S. F., Chan, Y. O., Luk, W., Nicholls, J. M., Peiris, J. S. M., & Lau, Y. L. (2005) · Blood · doi:10.1182/blood-2004-10-4166 · Cited by 471
Virus factories: associations of cell organelles for viral replication and morphogenesis
Novoa, R. R., Calderita, G., Arranz, R., Fontana, J., Granzow, H., & Risco, C. (2005) · Biology of the Cell · doi:10.1042/bc20040058 · Cited by 471
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
“C6 systems Pre-clinical development Phase 1 Clinical testing starting by September 2020 Ebola, HIV, RSV Altimmune Intranasal COVID-19 vaccine Recombinant viral vector/Non-replicating Adenovirus -based NasoVAX expressing SARS2-CoV S protein Pre-clinical development Animal testing imminent /Clinical testing is initially…”
InfluentialKariwa, H., Fujii, N., & Takashima, I. (2006) · Dermatology · doi:10.1159/000089211 · Cited by 458
“Although the epidemic seemed to be controlled during the summer of 2003, laboratory-associated infections appeared in Singapore in September 2003, in Taiwan in December 2003 and in Beijing in April 2004. At the end of 2003, a new series of probable SARS cases, which may have been unrelated to laboratory sources of inf…”
BackgroundChen, Y., Cai, H., Pan, J., Xiang, N., Tien, P., Ahola, T., & Guo, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808790106 · Cited by 457
Axonal Transport Enables Neuron-to-Neuron Propagation of Human Coronavirus OC43
Dubé, M., Le Coupanec, A., Wong, A. H. M., Rini, J. M., Desforges, M., & Talbot, P. J. (2018) · Journal of Virology · doi:10.1128/jvi.00404-18 · Cited by 452
Boron Containing Compounds as Protease Inhibitors
Smoum, R., Rubinstein, A., Dembitsky, V. M., & Srebnik, M. (2012) · Chemical Reviews · doi:10.1021/cr608202m · Cited by 450
Preparedness and response to COVID-19 in Saudi Arabia: Building on MERS experience
Algaissi, A. A., Alharbi, N. K., Hassanain, M., & Hashem, A. M. (2020) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2020.04.016 · Cited by 442
Coronavirus Replication Complex Formation Utilizes Components of Cellular Autophagy
Prentice, E., Jerome, W. G., Yoshimori, T., Mizushima, N., & Denison, M. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306124200 · Cited by 450
COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
Miesbach, W., & Makris, M. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620938149 · Cited by 443
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
Chu, H., Zhou, J., Wong, B. H.-Y., Li, C., Chan, J. F.-W., Cheng, Z.-S., Yang, D., Wang, D., Lee, A. C.-Y., Li, C., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv380 · Cited by 448
“SARS patients during the acute phase of infection [44, 45].”
BackgroundMordstein, M., Neugebauer, E., Ditt, V., Jessen, B., Rieger, T., Falcone, V., Sorgeloos, F., Ehl, S., Mayer, D., Kochs, G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.00272-10 · Cited by 443
Self-citationLiu, L., Wei, Q., Alvarez, X., Wang, H., Du, Y., Zhu, H., Jiang, H., Zhou, J., Lam, P., Zhang, L., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02292-10 · Cited by 450
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
Martinez, M. A. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00399-20 · Cited by 444
Aboubakr, H. A., Sharafeldin, T. A., & Goyal, S. M. (2021) · Transboundary and Emerging Diseases · doi:10.1111/tbed.13707 · Cited by 443
Ruan, Y., Wei, C. L., Ling, A. E., Vega, V. B., Thoreau, H., Se Thoe, S. Y., Chia, J.-M., Ng, P., Chiu, K. P., Lim, L., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13414-9 · Cited by 437
Gao, T., Zhu, L., Liu, H., Zhang, X., Wang, T., Fu, Y., Li, H., Dong, Q., Hu, Y., Zhang, Z., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01133-5 · Cited by 436
Geller, C., Varbanov, M., & Duval, R. E. (2012) · Viruses · doi:10.3390/v4113044 · Cited by 434
Multiple Enzymatic Activities Associated with Severe Acute Respiratory Syndrome Coronavirus Helicase
Ivanov, K. A., Thiel, V., Dobbe, J. C., van der Meer, Y., Snijder, E. J., & Ziebuhr, J. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5619-5632.2004 · Cited by 435
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444
DeDiego, M. L., Álvarez, E., Almazán, F., Rejas, M. T., Lamirande, E., Roberts, A., Shieh, W.-J., Zaki, S. R., Subbarao, K., & Enjuanes, L. (2007) · Journal of Virology · doi:10.1128/jvi.01467-06 · Cited by 438
Evolutionary history, potential intermediate animal host, and cross‐species analyses of SARS‐CoV‐2
Li, X., Zai, J., Zhao, Q., Nie, Q., Li, Y., Foley, B. T., & Chaillon, A. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25731 · Cited by 434
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
Wang, N., Shang, J., Jiang, S., & Du, L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00298 · Cited by 425
Thai, H. T. C., Le, M. Q., Vuong, C. D., Parida, M., Minekawa, H., Notomi, T., Hasebe, F., & Morita, K. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.5.1956-1961.2004 · Cited by 422
Metadata
- Authors
- Drosten, C., Günther, S., Preiser, W., van der Werf, S., Brodt, H.-R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A. M., Berger, A., Burguière, A.-M., Cinatl, J., Eickmann, M., Escriou, N., Grywna, K., Kramme, S., Manuguerra, J.-C., Müller, S., Rickerts, V., Stürmer, M., Vieth, S., Klenk, H.-D., Osterhaus, A. D. M. E., Schmitz, H., & Doerr, H. W.
- Affiliations
- Goethe University Frankfurt (DE)
- From the Bernhard Nocht Institute for Tropical Medicine, National Reference Center for Tropical Infectious Diseases, Hamburg (C.D., S.G., M.P., K.G., S.K., S.M., S.V., H.S.); the Institute of Medical Virology (W.P., H.R., A.B., J.C., M.S., H.W.D.) and the Medical Clinic III (H.-R.B., V.R.), Johann Wolfgang Goethe University, Frankfurt am Main; and the Institute of Virology, Philipps University, Marburg (S.B., L.K., M.E., H.-D.K.) — all in Germany; the Pasteur Institute, Molecular Genetics of Respiratory...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-15
- Volume
- 348
- Issue
- 20
- Pages
- 1967-1976
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2132260239
- Semantic Scholar
- 79116f5bb552a1a23de85d03899ab0b3763c81ee
- Cited by
- 4,574
- References
- 10
- Citations by year
- 2026: 40 · 2025: 91 · 2024: 141 · 2023: 193 · 2022: 361 · 2021: 646 · 2020: 913 · 2019: 50 · 2018: 45 · 2017: 49 · 2016: 60 · 2015: 65 · 2014: 91 · 2013: 83 · 2012: 93
- FWCI
- 222.93
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- HAL (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS, novel coronavirus, SARS-CoV, virus identification, viral RNA detection, seroconversion, fecal viral shedding, plasma viral RNA
- MeSH terms
- Adult, Amino Acid Sequence, Animals, Base Sequence, Cattle, Disease Outbreaks, DNA, Viral, Female, Humans, Male, Molecular Sequence Data, Phylogeny, RNA, Viral, Sequence Homology, Nucleic Acid, Sputum, Polymerase Chain Reaction, Coronavirus, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.